Study objective Inhaled bronchodilators are the first-line pharmacotherapy against COPD.
The purpose of the present study was to investigate the effects of β 2-agonists and …

Study objective To evaluate the impact of a week-long course of inhaled albuterol compared
with ipratropium on expiratory peak flow, exercise performance, and dyspnea in patients …

Introduction Inhaled anticholinergic drugs are often recommended for use as a first-line
therapy for patients with COPD because they provide similar or more effective …

One of the major goals of bronchodilator therapy in patients with COPD is to decrease
airflow limitation in the airways and, as a consequence, improve dyspnea and exercise …

Although long-acting inhaled β2-agonists improve various outcome measures in COPD, no
double-blind study has yet shown a significant effect of these drugs on exercise capacity. In …

Spacing devices improve lung deposition of aerosols from metered dose inhalers (MDI) but
it is sometimes difficult for dyspnoeic patients to perform maximal breaths with breath-holds …

FEV 1/FVC%, ipratropium significantly improved FEV 1, FEF 25-75, peak oxygen uptake and
minute ventilation. Moreover, both of the medications increased exercise time. There were …

Both oxygen therapy and bronchodilators reduce exertional breathlessness and improve
exercise tolerance in patients with stable chronic obstructive pulmonary disease (COPD) …

Background: Inhaled bronchodilators can increase exercise capacity in chronic obstructive
pulmonary disease (COPD) by reducing dynamic hyperinflation, but treatment is not always …

Inhaled anticholinergics may be the first-line therapy for stable COPD. However, the effect of
inhaled anticholinergic agents on exercise capacity is still controversial. Fourteen patients …